Abstract Number: 1940 • ACR Convergence 2023
A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…Abstract Number: 059 • 2023 Pediatric Rheumatology Symposium
Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem. Despite recent advances, there remain key unanswered questions…Abstract Number: 098 • 2023 Pediatric Rheumatology Symposium
Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series
Background/Purpose: Given the high prevalence of intestinal lung disease (ILD) in systemic sclerosis (SSc) and the low sensitivity of pulmonary function testing for diagnosing ILD,…Abstract Number: L16 • ACR Convergence 2022
Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…Abstract Number: 0533 • ACR Convergence 2022
Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity
Background/Purpose: Presence of systemic anti-CCP-IgG antibodies in individuals without inflammatory arthritis (IA) strongly predicts developing future classified RA. However, published data also demonstrate that 50-70%…Abstract Number: 1788 • ACR Convergence 2022
Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time
Background/Purpose: Hyperuricaemia is common in pulmonary hypertension (PH) occurring in up to 80% of patients with serum uric acid levels(sUA) correlating with poor PH outcomes.…Abstract Number: 0675 • ACR Convergence 2022
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…Abstract Number: 1835 • ACR Convergence 2022
Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease
Background/Purpose: Sarcoidosis is a multiorgan granulomatous disease with a prevalence of 60 per 100,000 in the United States.1 Given the low prevalence of both sarcoidosis…Abstract Number: 0804 • ACR Convergence 2022
Incidence and Risk Factors of Active Tuberculosis in Patients with Rheumatic Diseases Complicated with Tuberculosis Infection: A Multicenter Prospective Cohort Study
Background/Purpose: China remains a high-burden country of both rheumatic disease (RD) and tuberculosis (TB) till today. Patients with RD are considered as a high-risk population…Abstract Number: 1844 • ACR Convergence 2022
Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital
Background/Purpose: Neurosarcoidosis (NS) is a severe complication of sarcoidosis. NS may be classified according to several subtypes. Data on therapy, including biological therapy (BT) is…Abstract Number: 0823 • ACR Convergence 2022
Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: A Systematic Literature Review
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, auto-inflammatory, somatic) syndrome is a newly described auto-inflammatory disease, characterised by somatic mutation of UBA1 [1]. A consistent feature…Abstract Number: 1881 • ACR Convergence 2022
Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals
Background/Purpose: Anti-transcriptional intermediary factor 1γ (anti-TIF 1γ) antibody is robustly linked with malignancy-associated dermatomyositis (DM) in adults, but its specificity varies widely between series. TIF…Abstract Number: 0944 • ACR Convergence 2022
Inconsistent Family Planning Documentation in Women with Interstitial Pneumonia with Autoimmune Features (IPAF)
Background/Purpose: Family planning discussions improve pregnancy outcomes in women with interstitial lung disease (ILD). Women with interstitial pneumonia with autoimmune features (IPAF), a subset of…Abstract Number: 1928 • ACR Convergence 2022
Idiopathic Pulmonary Capillaritis Within the Spectrum of Pediatric Diffuse Alveolar Hemorrhage
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening syndrome with bleeding from the pulmonary microvasculature. It is classified as pulmonary capillaritis if histology shows neutrophilic…Abstract Number: 1049 • ACR Convergence 2022
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »